Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia.

Leukemia & lymphoma - 1 Jan 2015

Chen Chen, Xu Wei, Yang Jing

Abstract excerpt

The treatment of young patient with acute myeloid leukemia (AML) has improved dramatically during the past several decades. However, management of elderly patients with AML still remains a challenge. A total of 56 elderly patients with de novo AML were treated with homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor (HCG). The overall response rate was 75% (60.7%% complete...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytarabine

Share to Granulocyte Colony-Stimulating Factor

Share to Karyotyping

Share to Leukemia, Myeloid, Acute

Share to Nucleophosmin

Share to Survival Analysis

Source

Identifiers

PMID: 24724783
DOI: 10.3109/10428194.2014.910774

Genes

NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia.PMID 24724783Read ↗

Clinical efficacy of decitabine‑containing induction chemotherapy in de novo non‑elderly acute myeloid leukemia.Semantic proximity Read ↗

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.Semantic proximity Read ↗

Chidamide and Decitabine in Combination with a HAG Priming Regimen for Acute Myeloid Leukemia with TP53 Mutation.Semantic proximity Read ↗

[Comparison of efficacy and prognostic factors in elderly acute myelogenous patients with MA or CAG induction chemotherapy regimen].Semantic proximity Read ↗

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009Semantic proximity Read ↗

XPO1 is a new target of homoharringtonine (HHT): Making NPMc+ AML cells much more sensitive to HHT treatment.Semantic proximity Read ↗

Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia.Semantic proximity Read ↗

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.Semantic proximity Read ↗

The role of hypomethylating agents in the treatment of elderly patients with AMLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.